» Articles » PMID: 17301127

Epstein-Barr Virus Transcription Activator Rta Upregulates Decoy Receptor 3 Expression by Binding to Its Promoter

Overview
Journal J Virol
Date 2007 Feb 16
PMID 17301127
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Decoy receptor 3 (DcR3) is a soluble decoy receptor belonging to the tumor necrosis factor receptor superfamily that is overexpressed in various malignant tumor types. DcR3 has been implicated in tumor cell survival by inhibiting apoptosis and by interfering with immune surveillance. A previous study showed that DcR3 expression is associated with Epstein-Barr virus (EBV)-positive lymphomas but rarely with non-EBV-positive B-cell lymphomas, suggesting that the presence of EBV may affect DcR3 expression. Here, we demonstrated enhanced DcR3 expression upon EBV reactivation in P3HR1 cells and in EBV-infected 293 cells. This enhancement, however, could not be detected in 293 cells infected with EBV with BRLF1 deleted. We found that EBV transactivator, Rta, could upregulate DcR3 expression by direct binding to an Rta-responsive element (RRE) located in the DcR3 promoter region and that this RRE is important for Rta-mediated DcR3 expression. Overexpressing CREB-binding protein (CBP) further enhanced Rta-dependent DcR3 expression, suggesting Rta-dependent DcR3 transcription activity is mediated by CBP. Previously, Rta was shown to enhance phosphatidylinositol-3 kinase (PI3-K) activity. However, Rta-transduced PI 3-K activity plays a minor role in DcR3 expression. This is the first report to demonstrate that Rta upregulates a cellular gene by direct binding to an RRE.

Citing Articles

Upregulation of IQGAP2 by EBV transactivator Rta and its influence on EBV life cycle.

Lin K, Weng L, Chen S, Lin S, Tsai C J Virol. 2023; 97(8):e0054023.

PMID: 37504571 PMC: 10506479. DOI: 10.1128/jvi.00540-23.


Epstein-Barr Virus Viral Processivity Factor EA-D Facilitates Virus Lytic Replication by Inducing Poly(ADP-Ribose) Polymerase 1 Degradation.

Lee S, Kim J, Chung W, Han J, Song M J Virol. 2022; 96(21):e0037122.

PMID: 36286483 PMC: 9645209. DOI: 10.1128/jvi.00371-22.


Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy.

Necasova I, Stojaspal M, Motycakova E, Brom T, Janovic T, Hofr C NAR Cancer. 2022; 4(1):zcac005.

PMID: 35252867 PMC: 8892037. DOI: 10.1093/narcan/zcac005.


Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.

Song L, Song M, Camargo M, Van Duine J, Williams S, Chung Y Gastric Cancer. 2021; 24(4):858-867.

PMID: 33661412 PMC: 8206016. DOI: 10.1007/s10120-021-01170-z.


Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-κB signalling.

Hou Y, Liang D, Liu Y, Chen H, Lou X BMC Biochem. 2018; 19(1):13.

PMID: 30587127 PMC: 6307204. DOI: 10.1186/s12858-018-0102-z.


References
1.
Yao Q, Rickinson A, Epstein M . A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer. 1985; 35(1):35-42. DOI: 10.1002/ijc.2910350107. View

2.
Hung C, Liu S . Characterization of the Epstein-Barr virus BALF2 promoter. J Gen Virol. 1999; 80 ( Pt 10):2747-2750. DOI: 10.1099/0022-1317-80-10-2747. View

3.
Rooney C, Taylor N, Countryman J, Jenson H, Kolman J, Miller G . Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A. 1988; 85(24):9801-5. PMC: 282869. DOI: 10.1073/pnas.85.24.9801. View

4.
Gill R, Ni J, Hunt J . Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes. Am J Pathol. 2002; 161(6):2011-7. PMC: 1850908. DOI: 10.1016/S0002-9440(10)64479-3. View

5.
Migone T, Zhang J, Luo X, Zhuang L, Chen C, Hu B . TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002; 16(3):479-92. DOI: 10.1016/s1074-7613(02)00283-2. View